Schiff looks to probiotics acquisition for growth
SALT LAKE CITY — Schiff Nutrition president and CEO Tarang Amin promised to infuse some new energy into the company with his appointment earlier this spring, and he wasted no time with the Schiff acquisition of two probiotic brands — Sustenex and Digestive Advantage — in June.
“I’m absolutely passionate about brand-building,” he told analysts in March. “Throughout my career, I’ve taken well-established brands and made them even stronger,” he said, referencing his success in building the Pantene and Bounty businesses.
Now Amin is hoping to do the same kind of brand-building in the supplement arena. With the Sustenex/Digestive Advantage purchase, Schiff gains access to the exclusive rights to use probiotic technology GanedenBC30 from Ganeden Biotech. “By acquiring the rights to the leading probiotics technology, we have entered a new, rapidly expanding category that creates accretive growth opportunities,” Amin said.
The probiotics category is presently growing at more than 20% on an annualized basis, according to Nutrition Business Journal.
Hyland’s to ‘Defend’ adults from colds with new line
NEW YORK — Hyland’s will attempt to parlay its success across its 4 Kids line of homeopathic solutions into the adult section with its recent launch of the Hyland’s Defend line. “We are seeing tremendous growth in our cold and cough 4 Kids,” noted Jay Borneman, chairman and CEO at Hyland’s.
A lot of that growth can be traced to increased awareness around the safety and efficacy associated with homeopathic cough-cold products for use to relieve a child’s cough-cold symptoms. The reasoning is that the parent who purchased that homeopathic solution for their child will be looking for a similar adult solution when they catch a cold.
According to the company, the Hyland’s brand already is recognized by parents for cold relief with Hyland’s Cold ’n Cough 4 Kids product sales growing by 250% per year. The Defend line includes three SKUs: Cold ’n Cough, Cold ’n Cough Nighttime and Sinus.
Three’s not a crowd: Top antacids hold their own
Good things come in three — like the three antacids that for the 52 weeks ended April 17 collectively generated more than $118 million in sales on top of the sales base they had established in the year-ago period.
Only two of those antacids were proton-pump inhibitors — Novartis’ Prevacid 24HR and Merck’s Zegerid OTC. Both are relatively new to the shelf, and neither are yet facing the volume of generic competition like Procter & Gamble’s PPI Prilosec OTC, which incidentally is still the best-selling antacid on the market by a more-than-$150-million margin in annual sales. The third antacid that still demands its fair share of heartburn relief is the venerable Tums — sales are up 198.4% to $51.7 million across food, drug and mass (excluding Walmart) for those 52 weeks ended April 17, according to SymphonyIRI Group data.
Throw Boehringer-Ingelheim’s Zantac 150 into that lineup, which didn’t lose all that many annual sales as it is down less than 0.1% with $72.3 million in sales despite competition from two new switch products, and the question asked by Drug Store News last year has been answered: There is still plenty of room on the antacids shelf.
The article above is part of the DSN Category Review Series. For the complete Antacids Mid-Year Report, including extensive charts, data and more analysis, click here.